(Q38079075)

28 August 2017

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults (English)

1 reference

28 August 2017

1 reference

Sara E Shinnick

1

1 reference

PubMed ID

23380527

28 August 2017

Mary L Browning

series ordinal

2

1 reference

PubMed ID

23380527

28 August 2017

Susannah E Koontz

series ordinal

3

1 reference

28 August 2017

4 February 2013

1 reference

Journal of Pediatric Oncology Nursing

28 August 2017

1 reference

28 August 2017

30

1 reference

28 August 2017

2

1 reference

28 August 2017

63-77

1 reference

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

28 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

21 January 2018

Asparaginase revisited

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Pegaspargase: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Use of ?-asparaginase in childhood ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Biology, risk stratification, and therapy of pediatric acute leukemias: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1043454212471728

21 January 2018

Identifiers

DOI

10.1177/1043454212471728

1 reference

28 August 2017

1 reference

PubMed ID

23380527